IP Library › Granted Patent US 7,928,064
Granted Patent B2
US 7,928,064 · App. 11/284,585 · Granted Apr 19, 2011

Transgenically produced antithrombin III

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,928,064
App. No.
11/284,585
Granted
Apr 19, 2011
Kind
B2
Abstract

This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.

Claims (6)

1. A method of treating a subject having an antithrombin III (ATIII) deficiency or inflammation, comprising:

administering to the subject a non-human mammal mammary gland produced recombinant antithrombin III (ATIII).

2. The method of claim 1 , wherein the mammary gland produced antithrombin III (ATIII) is produced in the mammary glands of a transgenic goat.

3. The method of claim 1 , wherein said non-human mammal is produced by microinjection procedures.

4. The method of claim 1 , wherein said antithrombin (III) is at least 90% pure as determined by ELISA.

5. The method of claim 1 , wherein the antithrombin III (ATIII) glycosylation varies from plasma-derived antithrombin III (ATIII) by the increased presence of GalNAc and reduction of sialic acid.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Mar 14, 2014
From: LFB BIOTECHNOLOGIES S.A.S.U.
To: GTC BIOTHERAPEUTICS, INC.
Reel/Frame 032448/0045 →
RELEASE OF SECURITY INTEREST Recorded Mar 11, 2014
From: GENERAL ELECTRIC CAPITAL CORPORATION
To: GTC BIOTHERAPEUTICS, INC.
Reel/Frame 032424/0230 →
CHANGE OF NAME Recorded Jul 18, 2013
From: GTC BIOTHERAPEUTICS, INC.
To: REVO BIOLOGICS, INC.
Reel/Frame 030831/0075 →
CHANGE OF NAME Recorded Sep 3, 2010
From: GENZYME TRANSGENICS CORPORATION
To: GTC BIOTHERAPEUTICS, INC.
Reel/Frame 024937/0709 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2010
From: DITULLIO, PAUL; MEADE, HARRY; COLE, EDWARD S.
To: GENZYME TRANSGENIC CORPORATION
Reel/Frame 024937/0796 →
SECURITY AGREEMENT Recorded Jan 16, 2009
From: GTC BIOTHERAPEUTICS, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 022119/0854 →
SECURITY AGREEMENT Recorded Dec 22, 2008
From: GTC BIOTHERAPEUTICS, INC.
To: LFB BIOTECHNOLOGIES S.A.S.U.
Reel/Frame 022019/0205 →